GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (LTS:0NZU) » Definitions » Operating Cash Flow per Share

Zealand Pharma AS (LTS:0NZU) Operating Cash Flow per Share : kr-8.17 (TTM As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma AS Operating Cash Flow per Share?

Zealand Pharma AS's operating cash flow per share for the three months ended in Jun. 2024 was kr-3.69. Zealand Pharma AS's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2024 was kr-8.17.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 25.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Zealand Pharma AS's Operating Cash Flow per Share or its related term are showing as below:

LTS:0NZU' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -229.7   Med: -20.25   Max: 68.2
Current: 25.2

During the past 13 years, Zealand Pharma AS's highest 3-Year average Operating Cash Flow per Share Growth Rate was 68.20% per year. The lowest was -229.70% per year. And the median was -20.25% per year.

LTS:0NZU's 3-Year OCF Growth Rate is ranked better than
74.35% of 1197 companies
in the Biotechnology industry
Industry Median: 3.5 vs LTS:0NZU: 25.20

Zealand Pharma AS Operating Cash Flow per Share Historical Data

The historical data trend for Zealand Pharma AS's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS Operating Cash Flow per Share Chart

Zealand Pharma AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.11 -17.95 -28.27 -20.40 -7.52

Zealand Pharma AS Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.03 -1.87 1.02 -3.63 -3.69

Competitive Comparison of Zealand Pharma AS's Operating Cash Flow per Share

For the Biotechnology subindustry, Zealand Pharma AS's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Price-to-Operating-Cash-Flow falls into.



Zealand Pharma AS Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Zealand Pharma AS's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=-425.668/56.589
=-7.52

Zealand Pharma AS's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Jun. 2024 )=Cash Flow from Operations (Q: Jun. 2024 )/Shares Outstanding (Diluted Average) (Q: Jun. 2024 )
=-231.329/62.688
=-3.69

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-8.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zealand Pharma AS Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma AS Business Description

Industry
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma AS Headlines

No Headlines